(−)-Oleocanthal as a c-Met Inhibitor for the Control of Metastatic Breast and Prostate Cancers

Abstract

The proto-oncogene receptor tyrosine kinase c-Met encodes the high-affinity receptor for hepatocyte growth factor (HGF). Dysregulation of the HGF‐c-Met pathway plays a significant oncogenic role in many tumors. Overexpression of c-Met is a prognostic indicator for some transitional cell carcinomas. Extra-virgin olive oil (EVOO) provides a variety of minor phenolic compounds with beneficial properties. (−)-Oleocanthal (1) is a naturally occurring minor secoiridoid isolated from EVOO, which showed potent anti-inflammatory activity via its ability to inhibit COX-1 and COX-2. It altered the structure of neurotoxic proteins believed to contribute to the debilitating effects of Alzheimer's disease. Computer-Assisted Molecular Design (CAMD) identified 1 as a potential virtual c-Met inhibitor hit. Oleocanthal inhibited the proliferation, migration, and invasion of the epithelial human breast and prostate cancer cell lines MCF7, MDA‐MB‐231, and PC-3, respectively, with an IC₅₀ range of 10–20 µM, and demonstrated anti-angiogenic activity via downregulating the expression of the microvessel density marker CD31 in endothelial colony forming cells with an IC₅₀ of 4.4 µM. It inhibited the phosphorylation of c-Met kinase in vitro in the Z′-LYTE™ assay, with an IC₅₀ value of 4.8 µM. (−)-Oleocanthal and EVOO can have potential therapeutic use for the control of c-Met-dependent malignancies.

Key words

breast cancer - extra‐virgin olive oil - (−)‐oleocanthal - c‐Met tyrosine kinase - migration and invasion - prostate cancer

References

• 1 Wang X, Le P, Liang C, Chan J, Kiewlich D, Miller T, Harris D, Sun L, Rice A, Vasile S, Blake R A, Howlett A R, Patel N, McMahon G, Lipson K E. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.  Mol Cancer Ther. 2003;  2 1085-1092
• 2 Prasad S, Phromnoi K, Yadav V R, Chaturvedi M M, Aggarwal B B. Targeting inflammatory pathways by flavonoids for prevention and treatment of cancer.  Planta Med. 2010;  76 1044-1063
• 3 Bellon S, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, Johnson C, Rose P, Long A, O'Connor A, Gu Y, Coxon A, Kim T, Tasker A, Burgess T, Dussault I. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.  J Biol Chem. 2008;  283 2675-2683
• 4 Peach M, Tan N, Choyke S, Giubellino A, Athauda G, Burke T, Nicklaus M, Bottaro D. Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening.  J Med Chem. 2009;  52 943-951
• 5 Chen C Y C. Discovery of novel inhibitors for c-Met by virtual screening and pharmacophore analysis.  J Chin Inst Chem Eng. 2008;  39 617-624
• 6 Bardelli A, Longati P, Williams T, Benvenuti S, Comoglio P M. A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth.  J Biol Chem. 1999;  274 29274-29281
• 7 Sattler M, Salgia R. The MET axis as a therapeutic target.  Update Cancer Ther. 2009;  3 109-118
• 8 Schiering N, Knapp S, Marconi M, Flocco M M, Cui J, Perego R, Rusconi L, Cristiani C. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a.  PNAS. 2003;  100 12654-12659
• 9 Wang W, Marimuthu A, Tsai J, Kumar A, Krupka H I, Zhang C, Powell B, Suzuki Y, Nguyen H, Tabrizizad M, Luu C, West B L. Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase.  PNAS. 2006;  103 3563-3568
• 10 Colomer R, Menéndez J. Mediterranean diet, olive oil and cancer.  Clin Transl Oncol. 2006;  8 15-21
• 11 Han J, Talorete T, Yamada P, Isoda H. Anti-proliferative and apoptotic effects of oleuropein and hydroxytyrosol on human breast cancer MCF-7 cells.  Cytotechnology. 2009;  59 45-53
• 12 Owen R, Mier W, Giacosa A, Hull W, Spiegelhalder B, Bartsch H. Phenolic compounds and squalene in olive oils: the concentration and antioxidant potential of total phenols, simple phenols, secoiridoids, lignansand squalene.  Food Chem Toxicol. 2000;  38 647-659
• 13 Gill C, Boyd A, McDermott E, McCann M, Servili M, Selvaggini R, Taticchi A, Esposto S, Montedoro G, McGlynn H, Rowland I. Potential anti-cancer effects of virgin olive oil phenols on colorectal carcinogenesis models in vitro.  Int J Cancer. 2005;  117 1-7
• 14 Montedoro G, Servili M, Baldioli R, Selvaggini E, Macchioni A. Simple and hydrolyzable compounds in virgin olive oil. 3. Spectroscopic characterizations of the secoiridoid derivatives.  J Agric Food Chem. 1993;  41 2228-2234
• 15 Menendez J A, Vazquez-Martin A, Colomer R, Brunet J, Carrasco-Pancorbo A, Garcia-Villalba R, Fernandez-Gutierrez A, Segura-Carretero A. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells.  BMC Cancer. 2007;  7 80
• 16 Menendez J A, Vazquez-Martin A, Garcia-Villalba R, Carrasco-Pancorbo A, Oliveras-Ferraros C, Fernandez-Gutierrez A, Segura-Carretero A. tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial extra-virgin olive oil (EVOO).  BMC Cancer. 2008;  8 377
• 17 Beauchamp G K, Keast R S, Morel D, Lin J, Pika J, Han Q, Lee C H, Smith A B, Breslin P A. Phytochemistry: ibuprofen-like activity in extra-virgin olive oil.  Nature. 2005;  437 45-46
• 18 Pitt J, Roth W, Lacor P, Smith A B, Blankenship M, Velasco P, De Felice F, Breslin P, Klein W L. Alzheimer's-associated Aβ oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal.  Toxicol Appl Pharmacol. 2009;  240 189-197
• 19 Jung I, Gurzu S, Raica M, Cîmpean A M, Szentirmay Z. The differences between the endothelial area marked with CD31 and CD105 in colorectal carcinomas by computer-assisted morphometrical analysis.  Rom J Morphol Embryol. 2009;  50 239-243
• 20 Smith A, Han Q, Breslin P, Beauchamp G. Synthesis and assignment of absolute configuration of (−)-oleocanthal: a potent, naturally occurring non-steroidal anti-inflammatory and anti-oxidant agent derived from extra virgin olive oils.  Org Lett. 2005;  7 5075-5078
• 21 Mudit M, Khanfar M, Muralidharan A, Thomas S, Shah G, van Soest R, El Sayed K. Discovery, design, and synthesis of anti-metastatic lead phenylmethylene hydantoins inspired by marine natural products.  Bioorg Med Chem. 2009;  17 1731-1738
• 22 Elnagar A, Wali V, Sylvester P, El Sayed K. Design and preliminary structure-activity relationship of redox-silent semisynthetic tocotrienol analogues as inhibitors for breast cancer proliferation and invasion.  Bioorg Med Chem. 2010;  18 755-768
• 23 Zama I N, Hutson T E, Elson P, Cleary J M, Choueiri T K, Heng D Y, Ramaiya N, Michaelson M D, Garcia J A, Knox J J, Escudier B, Rini B I. Sunitinib rechallenge in metastatic renal cell carcinoma patients.  Cancer. 2010;  116 5400-5406
• 24 SYBYL Molecular Modeling Software, version 8.0; Tripos Associates: St. Louis, MO, 2007; Technical tips online. Available at. http://www.tripos.com Accessed August 01, 2010
• 25 Welch W, Ruppert J, Jain A. Hammerhead: fast, fully automated docking of flexible ligands to protein binding sites.  Chem Biol. 1996;  3 449-462
• 26 Jain A N. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine.  J Med Chem. 2003;  46 499-511
• 27 Heiden W, Goetze T, Brickmann J. Fast generation of molecular surfaces from 3D data fields with an enhanced “marching cube” algorithm.  J Comp Chem. 1993;  14 246-250
• 28 Borghesani P, Peyrin J, Klein R, Rubin J, Carter A, Schwartz P, Luster A, Corfas G, Segal R. BDNF stimulates migration of cerebellar granule cells.  Development. 2002;  6 1435-1442
• 29 Rodems S M, Hamman B D, Lin C, Zhao J, Shah S, Heidary D, Makings L, Stack J H, Pollok B A. A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases.  Assay Drug Dev Technol. 2002;  1 9-19